{rfName}
Ad

Indexed in

License and use

Citations

25

Altmetrics

Analysis of institutional authors

Perez Gisbert, Francisco JavierAuthorChaparro MAuthorValenzuela CAuthor
Share
Publications
>
Letters

Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease

Publicated to:WORLD JOURNAL OF GASTROENTEROLOGY. 21 (7): 2260-2262 - 2015-02-21 21(7), DOI: 10.3748/wjg.v21.i7.2260

Authors: Jose Casanova, Maria; Chaparro, Maria; Valenzuela, Claudia; Cisneros, Carolina; Gisbert, Javier P

Affiliations

Hosp Univ Princesa, CIBEREHD, Inst Invest Sanitaria Princesa IIS IP, Dept Gastroenterol, Madrid 28002, Spain - Author
Hosp Univ Princesa, Dept Pneumol, Madrid 28002, Spain - Author
Hospital Universitario de la Princesa - Author

Abstract

There are several reports of anti-tumor necrosis factor (TNF)-induced lung disease, especially in patients with rheumatologic diseases. Adalimumab is an anti-TNF drug used to induce and maintain remission in patients with immune-mediated diseases, such as Crohn's disease. Although pulmonary disorders could be an extra-intestinal manifestation of inflammatory bowel disease, biologic therapy could also be a cause of lung injury. Only few cases of adalimumab-induced lung toxicity have been reported, and the majority of them were in patients with rheumatologic diseases. Lung injury secondary to anti-TNF therapy should, after ruling out other etiologies, be considered in patients who have a temporal association between the onset of respiratory symptoms and the exposure to these drugs. A compatible pattern in the biopsy and the clinical improvement after discontinuation of the anti-TNF drug would strongly support the diagnosis.

Keywords
adalimumabanti-tumor necrosis factorcrohn’s diseaseAdalimumabAnti-tumor necrosis factorCrohn's diseaseInfliximab therapyInterstitial pneumoniaRheumatoid-arthritisTnf

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal WORLD JOURNAL OF GASTROENTEROLOGY due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 3.16, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-14, the following number of citations:

  • WoS: 5
  • Scopus: 14
  • Europe PMC: 6
  • OpenCitations: 12
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-14:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 36 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.